San Diego Life Sciences Roundup: Regulus, Aragon, Cytori, & More

10/5/12Follow @bvbigelow

(Page 2 of 3)

its existing private investors. The closing was part of a plan to raise $76 million needed to fund three late-stage trials of the company’s liver therapy. The company has raised more than $75 million since it was founded nine years ago.

The Qualcomm Foundation awarded a $3.75 million grant to San Diego’s Scripps Health and its affiliated Scripps Translational Science Institute to support the development of innovative digital health technologies. Scripps said the funding would advance clinical trials of advanced biosensor systems, the creation of rapid diagnostic tests intended to match patients with the prescribed drug that’s best-suited for their genetic makeup, and the development of apps and sensors for tracking and predicting heart attacks, Type 1 diabetes, and certain cancers.

—San Diego’s Cytori Therapeutics (Nasdaq: CYTX) said it received a contract from the Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) that could be worth as much as $106 million. The contract calls for Cytori to develop its stem cell therapy technology to treat thermal burns associated with radiation exposure and injury. The company says the contract is intended to create a new treatment following a mass casualty event.

—San Diego-based Senomyx (NASDAQ: SNMX) said the FDA has determined that the company’s new flavor ingredient, known as S9632, meets criteria established for additives that are Generally Recognized As Safe (GRAS). The finding enables S9632 to be used in certain drinks and food products. Senomyx said S9632 can be used to restore … Next Page »

Bruce V. Bigelow is the editor of Xconomy San Diego. You can e-mail him at bbigelow@xconomy.com or call (619) 669-8788 Follow @bvbigelow

Single Page Currently on Page: 1 2 3 previous page

By posting a comment, you agree to our terms and conditions.